

Alicia RodrÃ-iguez-GascÃ³n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3925705/publications.pdf>

Version: 2024-02-01

51
papers

2,130
citations

304743

22
h-index

233421

45
g-index

52
all docs

52
docs citations

52
times ranked

3202
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study. <i>Journal of Intensive Care</i> , 2022, 10, 21.	2.9	6
2	mRNA delivery technologies: Toward clinical translation. <i>International Review of Cell and Molecular Biology</i> , 2022, , 207-293.	3.2	5
3	Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease. <i>Nanomaterials</i> , 2022, 12, 2339.	4.1	1
4	Evaluation of the adequacy of the antimicrobial therapy of invasive <i>Haemophilus influenzae</i> infections: A pharmacokinetic/pharmacodynamic perspective. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2021, 39, 65-71.	0.5	6
5	Evaluation of the adequacy of the antimicrobial therapy of invasive <i>Haemophilus influenzae</i> infections: A pharmacokinetic/pharmacodynamic perspective. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2021, 39, 65-71.	0.3	0
6	Î±-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice. <i>Pharmaceutics</i> , 2021, 13, 771.	4.5	12
7	Pharmacokinetic/pharmacodynamic evaluation of the antimicrobial therapy of pneumococcal invasive disease in adults in post-PCV13 vaccine period in Madrid, Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2145-2152.	2.9	1
8	Quantification of Ceftaroline in Human Plasma Using High-Performance Liquid Chromatography with Ultraviolet Detection: Application to Pharmacokinetic Studies. <i>Pharmaceutics</i> , 2021, 13, 959.	4.5	2
9	Pharmacokinetic/Pharmacodynamic Analysis of Tedizolid Phosphate Compared to Linezolid for the Treatment of Infections Caused by Gram-Positive Bacteria. <i>Antibiotics</i> , 2021, 10, 755.	3.7	6
10	The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials. <i>Pharmaceutics</i> , 2021, 13, 833.	4.5	46
11	mRNA-Based Nanomedicinal Products to Address Corneal Inflammation by Interleukin-10 Supplementation. <i>Pharmaceutics</i> , 2021, 13, 1472.	4.5	11
12	Population Pharmacokinetics of Levetiracetam and Dosing Evaluation in Critically Ill Patients with Normal or Augmented Renal Function. <i>Pharmaceutics</i> , 2021, 13, 1690.	4.5	10
13	Molecular Epidemiology, Antimicrobial Surveillance, and PK/PD Analysis to Guide the Treatment of <i>Neisseria gonorrhoeae</i> Infections. <i>Pharmaceutics</i> , 2021, 13, 1699.	4.5	5
14	<i>Pseudomonas aeruginosa</i> Susceptibility in Spain: Antimicrobial Activity and Resistance Suppression Evaluation by PK/PD Analysis. <i>Pharmaceutics</i> , 2021, 13, 1899.	4.5	5
15	Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic/pharmacodynamic perspective. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2020, 38, 306-311.	0.3	1
16	Topical Administration of SLN-Based Gene Therapy for the Treatment of Corneal Inflammation by De Novo IL-10 Production. <i>Pharmaceutics</i> , 2020, 12, 584.	4.5	17
17	Nucleic Acid Delivery by Solid Lipid Nanoparticles Containing Switchable Lipids: Plasmid DNA vs. Messenger RNA. <i>Molecules</i> , 2020, 25, 5995.	3.8	28
18	Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives. <i>Nanomaterials</i> , 2020, 10, 364.	4.1	138

#	ARTICLE	IF	CITATIONS
19	Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective. <i>International Journal of Infectious Diseases</i> , 2020, 93, 329-338.	3.3	36
20	Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation. <i>Pharmaceutics</i> , 2020, 12, 54.	4.5	22
21	Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic/pharmacodynamic perspective. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 306-311.	0.5	9
22	Gene-terapia: Ikuspegi terapeutiko berria begietako gaitzen tratamenduan. <i>Ekaia (journal)</i> , 2020, , 31-48.	0.0	0
23	Pharmacokinetic/pharmacodynamic analysis as a tool for surveillance of the activity of antimicrobials against <i>Pseudomonas aeruginosa</i> strains isolated in critically ill patients. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 380-386.	0.5	11
24	MMP-9 Downregulation with Lipid Nanoparticles for Inhibiting Corneal Neovascularization by Gene Silencing. <i>Nanomaterials</i> , 2019, 9, 631.	4.1	18
25	Susceptibility of <i>Pseudomonas aeruginosa</i> and antimicrobial activity using PK/PD analysis: an 18-year surveillance study. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2019, 37, 626-633.	0.3	0
26	Gene Therapy. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2019, 171, 321-368.	1.1	12
27	Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment. <i>Journal of Critical Care</i> , 2019, 50, 69-76.	2.2	27
28	Susceptibility of <i>Pseudomonas aeruginosa</i> and antimicrobial activity using PK/PD analysis: an 18-year surveillance study. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 626-633.	0.5	9
29	Augmented Renal Clearance in Critically Ill Patients: A Systematic Review. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1107-1121.	3.5	144
30	Gene delivery in the cornea: in vitro & ex vivo evaluation of solid lipid nanoparticle-based vectors. <i>Nanomedicine</i> , 2018, 13, 1847-1854.	3.3	22
31	Targeting corneal inflammation by gene therapy: Emerging strategies for keratitis. <i>Experimental Eye Research</i> , 2018, 176, 130-140.	2.6	23
32	Nonviral Delivery Systems for Gene Therapy for Retina and Posterior Segment Disease. , 2018, , 131-149.		0
33	Nanostructured lipid carriers as oral delivery systems for poorly soluble drugs. <i>Journal of Drug Delivery Science and Technology</i> , 2017, 42, 144-154.	3.0	62
34	Structural recovery of the retina in a retinoschisin-deficient mouse after gene replacement therapy by solid lipid nanoparticles. <i>Biomaterials</i> , 2016, 90, 40-49.	11.4	81
35	Silencing of hepatitis C virus replication by a non-viral vector based on solid lipid nanoparticles containing a shRNA targeted to the internal ribosome entry site (IRES). <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 146, 808-817.	5.0	23
36	Applications of lipid nanoparticles in gene therapy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 109, 184-193.	4.3	88

#	ARTICLE	IF	CITATIONS
37	Nanostructured lipid carriers: Promising drug delivery systems for future clinics. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 143-161.	3.3	488
38	Development and validation of a LC-MS assay for the quantification of ikh12 a novel anti-tumor candidate in rat plasma and tissues and its application in a pharmacokinetic study. <i>Biomedical Chromatography</i> , 2015, 29, 1249-1258.	1.7	0
39	Population pharmacokinetic models for cefuroxime and metronidazole used in combination as prophylactic agents in colorectal surgery: Model-based evaluation of standard dosing regimens. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 504-511.	2.5	16
40	Solid lipid nanoparticles as non-viral vector for the treatment of chronic hepatitis C by RNA interference. <i>International Journal of Pharmaceutics</i> , 2015, 479, 181-188.	5.2	24
41	Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. <i>Journal of Infection and Chemotherapy</i> , 2015, 21, 319-329.	1.7	169
42	Vaginal gene therapy. <i>Advanced Drug Delivery Reviews</i> , 2015, 92, 71-83.	13.7	32
43	Treatment of ocular disorders by gene therapy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 95, 331-342.	4.3	61
44	Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles. <i>International Journal of Nanomedicine</i> , 2014, 9, 1833.	6.7	65
45	Lipid Nanoparticles as Carriers for RNAi against Viral Infections: Current Status and Future Perspectives. <i>BioMed Research International</i> , 2014, 2014, 1-17.	1.9	53
46	Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. <i>International Journal of Pharmaceutics</i> , 2014, 468, 105-111.	5.2	72
47	Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 180-189.	3.0	55
48	New gene delivery system based on oligochitosan and solid lipid nanoparticles: "in vitro" and "in vivo" evaluation. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 50, 484-491.	4.0	39
49	Gene Therapy for Fabry Disease: A Review of the Literature. <i>BioDrugs</i> , 2013, 27, 237-246.	4.6	25
50	Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: The importance of the entry pathway. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011, 79, 495-502.	4.3	87
51	Population Pharmacokinetics of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy. <i>Clinical Pharmacokinetics</i> , 2008, 47, 173-180.	3.5	56